New drug duo targets aggressive colon cancer mutation in major trial
NCT ID NCT06008119
First seen Nov 01, 2025 · Last updated Apr 12, 2026 · Updated 25 times
Summary
This study is testing whether a combination of two targeted drugs (tunlametinib and vemurafenib) works better than standard chemotherapy for people with advanced colorectal cancer that has a specific genetic change called BRAF V600E. The trial is for adults whose cancer has continued to grow despite at least one prior treatment. Researchers will measure if the drug combination helps patients live longer without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Oncology Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.